R&D Strategy

DNDi will use a virtual R&D model, with the aim of improving the health and quality of life of people suffering from neglected diseases. The primary R&D objective is to make six to eight new treatments available to patients by 2014 and to have a robust pipeline behind it.

Through four key processes (intelligence, project acquisition, product development, project & portfolio management), DNDi will fill the pipeline at all stages of development with a mix of short-, medium-, and long-term projects.

DNDi is proactively developing a portfolio through the identification of:

1) enduring unmet patient needs;
2) R&D opportunities such as candidate compounds and improved formulations to address such needs;
3) possible organisations to partner with in the R&D process;
4) and adequate funding to secure.

Concerted efforts that will harness discovery activities targeting all three primary diseases will be made so that the most promising anti-parasitic candidates are sourced for each disease. On a disease basis, the portfolio will be managed taking into account gap identification within the product portfolio, the pipeline projections, and strategic priorities.

By 2014, the objectives of DNDi are to:

• Deliver four lead optimization projects in total for the three primary diseases;
• Deliver one new drug and one new co-administration for HAT;
• Deliver three new drugs and two new co-administrations for VL;
• Deliver one new treatment for Chagas disease.

R&D Strategy (full text) (126KB)